Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1986 Feb;144(2):185–194.

New Developments in the Treatment of Gram-Negative Bacteremia

Mark A Jacobson, Lowell S Young
PMCID: PMC1306556  PMID: 3513451

Abstract

Gram-negative bacteremia is an increasingly important nosocomial infectious problem. Endotoxin, endorphins, leukocyte agglutination and deficient opsonization all appear to be major factors in the pathogenesis of Gram-negative septic shock. Outcome has previously correlated best to underlying disease state. With appropriate double antibiotic therapy and hemodynamic support, however, mortality has decreased even for neutropenic patients. Corticosteroids, naloxone, granulocyte transfusions and immunotherapy are experimental adjunctive modes of therapy that offer hope for even better survival in the future.

Full text

PDF
185

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alavi J. B., Root R. K., Djerassi I., Evans A. E., Gluckman S. J., MacGregor R. R., Guerry D., Schreiber A. D., Shaw J. M., Koch P. A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N Engl J Med. 1977 Mar 31;296(13):706–711. doi: 10.1056/NEJM197703312961302. [DOI] [PubMed] [Google Scholar]
  2. Anderson E. T., Young L. S., Hewitt W. L. Antimicrobial synergism in the therapy of gram-negative rod bacteremia. Chemotherapy. 1978;24(1):45–54. doi: 10.1159/000237759. [DOI] [PubMed] [Google Scholar]
  3. Braude A. I., Ziegler E. J., McCutchan J. A., Douglas H. Immunization against nosocomial infection. Am J Med. 1981 Feb;70(2):463–466. doi: 10.1016/0002-9343(81)90789-0. [DOI] [PubMed] [Google Scholar]
  4. Bryan C. S., Reynolds K. L., Brenner E. R. Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis. 1983 Jul-Aug;5(4):629–638. doi: 10.1093/clinids/5.4.629. [DOI] [PubMed] [Google Scholar]
  5. Bryant R. E., Hood A. F., Hood C. E., Koenig M. G. Factors affecting mortality of gram-negative rod bacteremia. Arch Intern Med. 1971 Jan;127(1):120–128. [PubMed] [Google Scholar]
  6. Burnie J. Naloxone in shock. Lancet. 1981 Apr 25;1(8226):942–942. doi: 10.1016/s0140-6736(81)91636-6. [DOI] [PubMed] [Google Scholar]
  7. Christensen R. D., Rothstein G., Anstall H. B., Bybee B. Granulocyte transfusions in neonates with bacterial infection, neutropenia, and depletion of mature marrow neutrophils. Pediatrics. 1982 Jul;70(1):1–6. [PubMed] [Google Scholar]
  8. Corrigan J. J., Jr Heparin therapy in bacterial septicemia. J Pediatr. 1977 Nov;91(5):695–700. doi: 10.1016/s0022-3476(77)81017-2. [DOI] [PubMed] [Google Scholar]
  9. Corrigan J. J., Jr, Kiernat J. F. Effect of heparin in experimental gram-negative septicemia. J Infect Dis. 1975 Feb;131(2):138–143. doi: 10.1093/infdis/131.2.138. [DOI] [PubMed] [Google Scholar]
  10. De Jongh C. A., Wade J. C., Schimpff S. C., Newman K. A., Finley R. S., Salvatore P. C., Moody M. R., Standiford H. C., Fortner C. L., Wiernik P. H. Empiric antibiotic therapy for suspected infection in granulocytopenic cancer patients: a comparison between the combination of moxalactam plus amikacin and ticarcillin plus amikacin. Am J Med. 1982 Jul;73(1):89–96. doi: 10.1016/0002-9343(82)90935-4. [DOI] [PubMed] [Google Scholar]
  11. Dorff G. J., Geimer N. F., Rosenthal D. R., Rytel M. W. Pseudomonas septicemia. Illustrated evolution of its skin lesion. Arch Intern Med. 1971 Oct;128(4):591–595. doi: 10.1001/archinte.128.4.591. [DOI] [PubMed] [Google Scholar]
  12. Faden A. I., Holaday J. W. Experimental endotoxin shock: the pathophysiologic function of endorphins and treatment with opiate antagonists. J Infect Dis. 1980 Aug;142(2):229–238. doi: 10.1093/infdis/142.2.229. [DOI] [PubMed] [Google Scholar]
  13. Fisher K., Berger B. W., Keusch G. T. Subepidermal bullae secondary to Escherichia coli septicemia. Arch Dermatol. 1974 Jul;110(1):105–106. [PubMed] [Google Scholar]
  14. Gahhos F. N., Chiu R. C., Hinchey E. J., Richards G. K. Endorphins in septic shock: hemodynamic and endocrine effects of an opiate receptor antagonist and agonist. Arch Surg. 1982 Aug;117(8):1053–1057. doi: 10.1001/archsurg.1982.01380320037010. [DOI] [PubMed] [Google Scholar]
  15. Gaya H. Rational basis for the choice of regimens for empirical therapy of sepsis in granulocytopenic patients. A report of the EORTC International Antimicrobial Therapy Project Group. Schweiz Med Wochenschr Suppl. 1983;14:49–57. [PubMed] [Google Scholar]
  16. Hammerschmidt D. E., White J. G., Craddock P. R., Jacob H. S. Corticosteroids inhibit complement-induced granulocyte aggregation. A possible mechanism for their efficacy in shock states. J Clin Invest. 1979 Apr;63(4):798–803. doi: 10.1172/JCI109365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Herzig R. H., Herzig G. P., Graw R. G., Jr, Bull M. I., Ray K. K. Successful granulocyte transfusion therapy for gram-negative septicemia. A prospectively randomized controlled study. N Engl J Med. 1977 Mar 31;296(13):701–705. doi: 10.1056/NEJM197703312961301. [DOI] [PubMed] [Google Scholar]
  18. Higby D. J., Yates J. W., Henderson E. S., Holland J. F. Filtration leukapheresis for granulocyte transfusion therapy. Clinical and laboratory studies. N Engl J Med. 1975 Apr 10;292(15):761–766. doi: 10.1056/NEJM197504102921501. [DOI] [PubMed] [Google Scholar]
  19. Hinshaw L. B., Beller B. K., Chang A. C., Flournoy D. J., Lahti R. A., Passey R. B., Archer L. T. Evaluation of naloxone for therapy of Escherichia coli shock. Species differences. Arch Surg. 1984 Dec;119(12):1410–1418. doi: 10.1001/archsurg.1984.01390240048009. [DOI] [PubMed] [Google Scholar]
  20. Hoffman S. L., Punjabi N. H., Kumala S., Moechtar M. A., Pulungsih S. P., Rivai A. R., Rockhill R. C., Woodward T. E., Loedin A. A. Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. N Engl J Med. 1984 Jan 12;310(2):82–88. doi: 10.1056/NEJM198401123100203. [DOI] [PubMed] [Google Scholar]
  21. Hunter K. W., Jr, Fischer G. W., Hemming V. G., Wilson S. R., Hartzman R. J., Woody J. N. Antibacterial activity of a human monoclonal antibody to haemophilus influenzae type B capsular polysaccharide. Lancet. 1982 Oct 9;2(8302):798–799. doi: 10.1016/s0140-6736(82)92682-4. [DOI] [PubMed] [Google Scholar]
  22. Jacob H. S., Craddock P. R., Hammerschmidt D. E., Moldow C. F. Complement-induced granulocyte aggregation: an unsuspected mechanism of disease. N Engl J Med. 1980 Apr 3;302(14):789–794. doi: 10.1056/NEJM198004033021407. [DOI] [PubMed] [Google Scholar]
  23. Jardin F., Sportiche M., Bazin M., Bourokba A., Margairaz A. Dobutamine: a hemodynamic evaluation in human septic shock. Crit Care Med. 1981 Apr;9(4):329–332. [PubMed] [Google Scholar]
  24. Jones R. J., Roe E. A., Gupta J. L. Low mortality in burned patients in a Pseudomonas vaccine trial. Lancet. 1978 Aug 19;2(8086):401–403. doi: 10.1016/s0140-6736(78)91868-8. [DOI] [PubMed] [Google Scholar]
  25. Keusch G. T., Ambinder E. P., Kovacs I., Goldberg J. D., Phillips D. M., Holland J. F. Role of opsonins in clinical response to granulocyte transfusion in granulocytopenic patients. Am J Med. 1982 Oct;73(4):552–563. doi: 10.1016/0002-9343(82)90336-9. [DOI] [PubMed] [Google Scholar]
  26. Klastersky J., Cappel R., Debusscher L. Effectiveness of betamethasone in management of severe infections. A double-blind study. N Engl J Med. 1971 Jun 3;284(22):1248–1250. doi: 10.1056/NEJM197106032842206. [DOI] [PubMed] [Google Scholar]
  27. Klastersky J. The role of the new penicillins and cephalosporins in the management of infection in granulocytopenic patients. Schweiz Med Wochenschr Suppl. 1983;14:64–69. [PubMed] [Google Scholar]
  28. Kreger B. E., Craven D. E., Carling P. C., McCabe W. R. Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med. 1980 Mar;68(3):332–343. doi: 10.1016/0002-9343(80)90101-1. [DOI] [PubMed] [Google Scholar]
  29. Kreger B. E., Craven D. E., McCabe W. R. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med. 1980 Mar;68(3):344–355. doi: 10.1016/0002-9343(80)90102-3. [DOI] [PubMed] [Google Scholar]
  30. Laurenti F., Ferro R., Isacchi G., Panero A., Savignoni P. G., Malagnino F., Palermo D., Mandelli F., Bucci G. Polymorphonuclear leukocyte transfusion for the treatment of sepsis in the newborn infant. J Pediatr. 1981 Jan;98(1):118–123. doi: 10.1016/s0022-3476(81)80556-2. [DOI] [PubMed] [Google Scholar]
  31. Love L. J., Schimpff S. C., Schiffer C. A., Wiernik P. H. Improved prognosis for granulocytopenic patients with gram-negative bacteremia. Am J Med. 1980 May;68(5):643–648. doi: 10.1016/0002-9343(80)90243-0. [DOI] [PubMed] [Google Scholar]
  32. Marks M. I., Ziegler E. J., Douglas H., Corbeil L. B., Braude A. I. Induction of immunity against lethal Haemophilus influenzae type b infection by Escherichia coli core lipopolysaccharide. J Clin Invest. 1982 Apr;69(4):742–749. doi: 10.1172/JCI110512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. McCabe W. R., Kreger B. E., Johns M. Type-specific and cross-reactive antibodies in gram-negative bacteremia. N Engl J Med. 1972 Aug 10;287(6):261–267. doi: 10.1056/NEJM197208102870601. [DOI] [PubMed] [Google Scholar]
  34. Naloxone in shock. Lancet. 1980 Dec 20;2(8208-8209):1360–1360. [PubMed] [Google Scholar]
  35. Neame P. B., Kelton J. G., Walker I. R., Stewart I. O., Nossel H. L., Hirsh J. Thrombocytopenia in septicemia: the role of disseminated intravascular coagulation. Blood. 1980 Jul;56(1):88–92. [PubMed] [Google Scholar]
  36. Peters W. P., Johnson M. W., Friedman P. A., Mitch W. E. Pressor effect of naloxone in septic shock. Lancet. 1981 Mar 7;1(8219):529–532. doi: 10.1016/s0140-6736(81)92865-8. [DOI] [PubMed] [Google Scholar]
  37. Pizzo P. A., Commers J., Cotton D., Gress J., Hathorn J., Hiemenz J., Longo D., Marshall D., Robichaud K. J. Approaching the controversies in antibacterial management of cancer patients. Am J Med. 1984 Mar;76(3):436–449. doi: 10.1016/0002-9343(84)90663-6. [DOI] [PubMed] [Google Scholar]
  38. Rosenshein M. S., Farewell V. T., Price T. H., Larson E. B., Dale D. C. The cost effectiveness of therapeutic and prophylactic leukocyte transfusion. N Engl J Med. 1980 May 8;302(19):1058–1062. doi: 10.1056/NEJM198005083021904. [DOI] [PubMed] [Google Scholar]
  39. Sanders C. C., Sanders W. E., Jr Microbial resistance to newer generation beta-lactam antibiotics: clinical and laboratory implications. J Infect Dis. 1985 Mar;151(3):399–406. doi: 10.1093/infdis/151.3.399. [DOI] [PubMed] [Google Scholar]
  40. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg. 1976 Sep;184(3):333–341. doi: 10.1097/00000658-197609000-00011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Sculier J. P., Klastersky J. Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med. 1984 Mar;76(3):429–435. doi: 10.1016/0002-9343(84)90662-4. [DOI] [PubMed] [Google Scholar]
  42. Sibbald W. J., Anderson R. R., Reid B., Holliday R. L., Driedger A. A. Alveolo-capillary permeability in human septic ARDS. Effect of high-dose corticosteroid therapy. Chest. 1981 Feb;79(2):133–142. doi: 10.1378/chest.79.2.133. [DOI] [PubMed] [Google Scholar]
  43. Skubitz K. M., Craddock P. R., Hammerschmidt D. E., August J. T. Corticosteroids block binding of chemotactic peptide to its receptor on granulocytes and cause disaggregation of granulocyte aggregates in vitro. J Clin Invest. 1981 Jul;68(1):13–20. doi: 10.1172/JCI110228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Sprung C. L., Caralis P. V., Marcial E. H., Pierce M., Gelbard M. A., Long W. M., Duncan R. C., Tendler M. D., Karpf M. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med. 1984 Nov 1;311(18):1137–1143. doi: 10.1056/NEJM198411013111801. [DOI] [PubMed] [Google Scholar]
  45. Swinburn W. R., Phelan P. Response to naloxone in septic shock. Lancet. 1982 Jan 16;1(8264):167–167. doi: 10.1016/s0140-6736(82)90411-1. [DOI] [PubMed] [Google Scholar]
  46. Tiengo M. Naloxone in irreversible shock. Lancet. 1980 Sep 27;2(8196):690–690. doi: 10.1016/s0140-6736(80)92723-3. [DOI] [PubMed] [Google Scholar]
  47. Vogler W. R., Winton E. F. A controlled study of the efficacy of granulocyte transfusions in patients with neutropenia. Am J Med. 1977 Oct;63(4):548–555. doi: 10.1016/0002-9343(77)90200-5. [DOI] [PubMed] [Google Scholar]
  48. WAISBREN B. A. Bacteremia due to gram-negative bacilli other than the Salmonella; a clinical and therapeutic study. AMA Arch Intern Med. 1951 Oct;88(4):467–488. doi: 10.1001/archinte.1951.03810100051005. [DOI] [PubMed] [Google Scholar]
  49. Wade J. C., Schimpff S. C., Newman K. A., Fortner C. L., Moody M. R., Young V. M., Wiernik P. H. Potential of mezlocillin as empiric single-agent therapy in febrile granulocytopenic cancer patients. Antimicrob Agents Chemother. 1980 Aug;18(2):299–306. doi: 10.1128/aac.18.2.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Wade J. C., Schimpff S. C., Newman K. A., Fortner C. L., Standiford H. C., Wiernik P. H. Piperacillin or ticarcillin plus amikacin. A double-blind prospective comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med. 1981 Dec;71(6):983–990. doi: 10.1016/0002-9343(81)90324-7. [DOI] [PubMed] [Google Scholar]
  51. Washington J. A., 2nd Blood cultures: principles and techniques. Mayo Clin Proc. 1975 Feb;50(2):91–98. [PubMed] [Google Scholar]
  52. Winslow E. J., Loeb H. S., Rahimtoola S. H., Kamath S., Gunnar R. M. Hemodynamic studies and results of therapy in 50 patients with bacteremic shock. Am J Med. 1973 Apr;54(4):421–432. doi: 10.1016/0002-9343(73)90038-7. [DOI] [PubMed] [Google Scholar]
  53. Winston D. J., Barnes R. C., Ho W. G., Young L. S., Champlin R. E., Gale R. P. Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients. Am J Med. 1984 Sep;77(3):442–450. doi: 10.1016/0002-9343(84)90100-1. [DOI] [PubMed] [Google Scholar]
  54. Winston D. J., Ho W. G., Gale R. P. Therapeutic granulocyte transfusions for documented infections. A controlled trial in ninety-five infectious granulocytopenic episodes. Ann Intern Med. 1982 Oct;97(4):509–515. doi: 10.7326/0003-4819-97-4-509. [DOI] [PubMed] [Google Scholar]
  55. Wolff S. M. The treatment of gram-negative bacteremia and shock. N Engl J Med. 1982 Nov 11;307(20):1267–1268. doi: 10.1056/NEJM198211113072010. [DOI] [PubMed] [Google Scholar]
  56. Wright D. G., Robichaud K. J., Pizzo P. A., Deisseroth A. B. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med. 1981 May 14;304(20):1185–1189. doi: 10.1056/NEJM198105143042001. [DOI] [PubMed] [Google Scholar]
  57. Young L. S., Martin W. J., Meyer R. D., Weinstein R. J., Anderson E. T. Gram-negative rod bacteremia: microbiologic, immunologic, and therapeutic considerations. Ann Intern Med. 1977 Apr;86(4):456–471. doi: 10.7326/0003-4819-86-4-456. [DOI] [PubMed] [Google Scholar]
  58. Young L. S., Meyer R. D., Armstrong D. Pseudomonas aeruginosa vaccine in cancer patients. Ann Intern Med. 1973 Oct;79(4):518–527. doi: 10.7326/0003-4819-79-4-518. [DOI] [PubMed] [Google Scholar]
  59. Young L. S. Symposium on infectious complications of neoplastic disease (Part II). Immunoprophylaxis and serotherapy of bacterial infections. Am J Med. 1984 Apr;76(4):664–671. doi: 10.1016/0002-9343(84)90292-4. [DOI] [PubMed] [Google Scholar]
  60. Ziegler E. J., McCutchan J. A., Fierer J., Glauser M. P., Sadoff J. C., Douglas H., Braude A. I. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med. 1982 Nov 11;307(20):1225–1230. doi: 10.1056/NEJM198211113072001. [DOI] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES